23 studies found for:    Open Studies | "Severe Combined Immunodeficiency"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Severe Combined Immunodeficiency"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
Conditions: X-linked Severe Combined Immunodeficiency;   XSCID;   SCID-X1;   Gamma C-Deficient SCID
Intervention: Other: Gene Transfer
2 Recruiting Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
Condition: Severe Combined Immunodeficiency Disease, X-linked
Interventions: Genetic: CL20-4i-EF/a-hyc-OPT;   Drug: Busulfan
3 Recruiting Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector
Condition: Severe Combined Immunodeficiency
Intervention: Biological: Gene transfer
4 Not yet recruiting Sirolimus Prophylaxis for aGVHD in TME SCID
Conditions: Severe Combined Immunodeficiency;   Transplacental Maternal Engraftment;   Stem Cell Transplant
Intervention: Drug: Sirolimus
5 Unknown  Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Genetic: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
6 Recruiting Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Conditions: Lymphohistiocytosis, Hemophagocytic;   Common Variable Immunodeficiency;   Severe Combined Immunodeficiency
Intervention:
7 Recruiting Use of G-CSF to Obtain Blood Cell Precursors
Conditions: Chronic Granulomatous Disease;   Healthy;   Immunologic Disease;   Leukocyte Adhesion Deficiency Syndrome;   Severe Combined Immunodeficiency
Intervention:
8 Recruiting Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
9 Recruiting Genetic Basis of Immunodeficiency
Condition: Severe Combined Immunodeficiency
Intervention:
10 Unknown  Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Conditions: Bone Marrow Failure;   Osteopetrosis;   Fanconi Anemia;   Severe Combined Immunodeficiency
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide 40;   Drug: Cyclophosphamide 30
11 Recruiting Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Conditions: Severe Combined Immunodeficiency;   Malignancy, Hematologic;   Neuroblastoma;   Neoplasm;   Mucopolysaccharidosis I
Intervention: Procedure: Venipuncture
12 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
13 Recruiting Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Conditions: Severe Combined Immunodeficiency (SCID);   Immunodeficiency With Predominant T-cell Defect, Unspecified;   Severe Chronic Neutropenia;   Chronic Granulomatous Disease (CGD);   Hyper IgE Syndromes;   Hyper IgM Deficiencies;   Wiskott-Aldrich Syndrome;   Mendelian Susceptibility to Mycobacterial Disease;   Common Variable Immune Deficiency (CVID)
Intervention: Biological: CD3/CD19 negative allogeneic hematopoietic stem cells
14 Recruiting Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)
Condition: Adenosine Deaminase (ADA)-Deficient SCID
Intervention: Genetic: EFS-ADA transduced CD34+ cells from the bone marrow
15 Not yet recruiting Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency
Conditions: Adenosine Deaminase Deficiency;   Severe Combined Immunodeficiencies (SCID)
Intervention: Genetic: EF1αS-ADA lentiviral vector transduced patient Cd34+ cells
16 Recruiting Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents
Condition: ADA-SCID
Intervention:
17 Recruiting Natural History Study of SCID Disorders
Conditions: SCID;   Leaky SCID;   Omenn Syndrome;   Reticular Dysgenesis;   ADA Deficiency;   XSCID
Intervention:
18 Recruiting Participation in a Research Registry for Immune Disorders
Conditions: ADA-SCID;   Adenosine Deaminase Deficiency;   Wiskott- Aldrich Syndrome;   Primary Immunodeficiencies;   Severe Combined Immune Deficiency
Intervention:
19 Recruiting Gene Therapy ADA Deficiency
Condition: Adenosine Deaminase Deficiency
Intervention: Biological: Intravenous infusion of transduced cells
20 Recruiting Patients Treated for SCID (1968-2010)
Conditions: SCID;   ADA-SCID;   XSCID;   Leaky SCID;   Omenn Syndrome;   Reticular Dysgenesis
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results
Indicates status has not been verified in more than two years